A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

被引：11

作者：

Zhou, Caicun ^{[1
]}

Hu, Yanping

Arkania, Ekaterine ^{[3
]}

Kilickap, Saadettin ^{[4
,21
]}

Ying, Kejing ^{[5
]}

Xu, Fei ^{[6
]}

Wu, Lin ^{[7
]}

Wang, Xiang ^{[8
]}

Viguro, Maksym ^{[20
]}

Makharadze, Tamta ^{[3
]}

Sun, Hongmei ^{[9
]}

Luo, Feng ^{[10
]}

Shi, Jianhua ^{[11
]}

Zang, Aimin ^{[12
]}

Pan, Yueyin ^{[13
]}

Chen, Zhendong ^{[14
]}

Jia, Zhongyao ^{[15
]}

Kuchava, Vladimer ^{[16
]}

Lu, Ping ^{[17
]}

Zhang, Ling ^{[18
]}

Cheng, Ying ^{[19
]}

Kang, Wenying ^{[20
]}

Wang, Qingyu ^{[19
]}

Yu, Haoyu ^{[20
]}

Li, Jing ^{[1
,20
]}

Zhu, Jun ^{[20
]}

机构：

[1] Shanghai Pulm Hosp, Dept Med Oncol, Shanghai 200433, Peoples R China

[2] Hubei Canc Hosp, Dept Med Oncol, Wuhan 430000, Peoples R China

[3] LTD Israeli Georgian Med Res Clin Helsicore, GE-0112 Tbilisi, Georgia

[4] Hacettepe Univ, Fac Med, Dept Med Oncol, TR-06230 Ankara, Turkiye

[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Pneumol, Hangzhou 310016, Peoples R China

[6] Nanchang Univ, Affiliated Hosp 1, Dept Pneumol, Nanchang 330006, Peoples R China

[7] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Med Oncol,Xiangya Sch Med, Changsha 410013, Peoples R China

[8] Xuzhou Cent Hosp, Dept Med Oncol, Xuzhou 221009, Peoples R China

[9] Jiamusi Tumor Hosp, Dept Med Oncol, Jiamusi 154007, Peoples R China

[10] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu 610041, Peoples R China

[11] Linyi Canc Hosp, Dept Med Oncol, Linyi 276000, Peoples R China

[12] Hebei Univ, Affiliated Hosp, Dept Med Oncol, Baoding 071000, Peoples R China

[13] Univ Sci & Technol China, Anhui Prov Hosp, Affiliated Hosp 1, Dept Med Oncol, Hefei 230001, Peoples R China

[14] Anhui Med Univ, Affiliated Hosp 2, Dept Med Oncol, Hefei 230601, Peoples R China

[15] Linyi Peoples Hosp, Dept Oncol, Linyi 276002, Peoples R China

[16] LTD Inst Clin Oncol, GE-0159 Tbilisi, Georgia

[17] Xinxiang Med Univ, Affiliated Hosp 1, Dept Oncol, Xinxiang 453100, Peoples R China

[18] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Peoples R China

[19] Jilin Canc Hosp, Dept Oncol, Changchun 130012, Peoples R China

[20] Shanghai Henlius Biotech Inc, Shanghai 200233, Peoples R China

[21] Istinye Univ, Fac Med, Dept Med Oncol, TR-34010 Istanbul, Turkiye

来源：

CANCER CELL | 2024年 / 42卷 / 02期

关键词：

NAB-PACLITAXEL; GEMCITABINE; CARBOPLATIN; PLACEBO; TRIAL;

D O I：

10.1016/j.ccell.2023.12.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Combining immunotherapy with chemotherapy can provide improved survival in advanced squamous nonsmall -cell lung cancer (NSCLC) patients without targetable gene alterations. 537 previously untreated patients with stage IIIB/IIIC or IV squamous NSCLC without targetable gene alterations were enrolled and randomized (2:1) to receive serplulimab 4.5 mg/kg or placebo, both in combination with nab-paclitaxel and carboplatin, intravenously in 3 -week cycles. The primary endpoint of progression -free survival (PFS) was met at the first interim analysis. At the second interim analysis, PFS benefit was maintained in serplulimab-chemotherapy group (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.42-0.67). At the final analysis, serplulimab-chemotherapy significantly improved median OS compared to placebo -chemotherapy (HR 0.73, 95% CI 0.58-0.93; p = 0.010). Grade R3 serplulimab or placebo -related adverse events occurred in 126 (35.2%) and 58 (32.4%) patients, respectively. Our results demonstrate that adding serplulimab to chemotherapy significantly improves survival in advanced squamous NSCLC patients, with manageable safety.

引用

页码：198 / 208.e3

页数：15

共 50 条

[31] Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer
Bondarenko, Igor M.
Ingrosso, Antonella
Bycott, Paul
Kim, Sinil
Cebotaru, Cristina L.
BMC CANCER, 2015, 15
[32] Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01)
Bennouna, Jaafar
Havel, Libor
Krzakowski, Maciej
Kollmeier, Jens
Gervais, Radj
Dansin, Eric
Serke, Monika
Favaretto, Adolfo
Szczesna, Aleksandra
Cobo, Manuel
Ciuffreda, Libero
Jassem, Jacek
Nicolini, Mario
Ramlau, Rodryg
Amoroso, Domenico
Melotti, Barbara
Almodovar, Teresa
Riggi, Marcello
Caux, Noel-Raphael
Vaissiere, Nathalie
Tan, Eng-Huat
CLINICAL LUNG CANCER, 2014, 15 (04) : 258 - 265
[33] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
Paz-Ares, L.
Luft, A.
Vicente, D.
Tafreshi, A.
Gumus, M.
Mazieres, J.
Hermes, B.
Senler, F. Cay
Csoszi, T.
Fulop, A.
Rodriguez-Cid, J.
Wilson, J.
Sugawara, S.
Kato, T.
Lee, K. H.
Cheng, Y.
Novello, S.
Halmos, B.
Li, X.
Lubiniecki, G. M.
Piperdi, B.
Kowalski, D. M.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) : 2040 - 2051
[34] Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Hellmann, Matthew D.
Rizvi, Naiyer A.
Goldman, Jonathan W.
Gettinger, Scott N.
Borghaei, Hossein
Brahmer, Julie R.
Ready, Neal E.
Gerber, David E.
Chow, Laura Q.
Juergens, Rosalyn A.
Shepherd, Frances A.
Laurie, Scott A.
Geese, William J.
Agrawal, Shruti
Young, Tina C.
Li, Xuemei
Antonia, Scott J.
LANCET ONCOLOGY, 2017, 18 (01) : 31 - 41
[35] Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer
Levy, B. P.
Signorovitch, J. E.
Yang, H.
Patterson-Lomba, O.
Xiang, C. Q.
Parisi, M.
CURRENT ONCOLOGY, 2019, 26 (03) : E300 - E308
[36] Immunotherapy or antiangiogenic therapy plus chemotherapy as first-line treatment of patients with PD-L1(-) advanced non-squamous non-small cell lung cancer in a Chinese cohort
Xia, Ruolan
Li, Yanying
Yang, Ling
Huang, Meijuan
CANCER MEDICINE, 2023, 12 (13): : 14282 - 14292
[37] Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?
Provencio, Mariano
de Las Penas, Ramon
Camps, Carlos
Artal, Angel
Massuti, Bartomeu
Cobo, Manuel
Javier Perez, Francisco
Sanchez, Antonio
Rosell, Rafael
LUNG CANCER, 2010, 68 (03) : 415 - 419
[38] A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Crawford, Jeffrey
Swanson, Paul
Schwarzenberger, Paul
Sandler, Alan
Prager, Diane
Zhang, Kathy
Freeman, Daniel J.
Johnson, Carol W.
Krishnan, Kartik
Johnson, David
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1510 - 1518
[39] Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
Lorusso, V
Crucitta, E
Panza, N
Silvestris, N
Guida, M
Carpagnano, F
Mancarella, S
Sambiasi, D
De Lena, M
ANNALS OF ONCOLOGY, 2002, 13 (12) : 1862 - 1867
[40] Non-small-cell lung cancer progression after first-line chemotherapy.
Lara Jr. P.N.
Lau D.H.
Gandara D.R.
Current Treatment Options in Oncology, 2002, 3 (1) : 53 - 58

← 1 2 3 4 5 →